Factors associated with HCV coinfection and preferences for HCV screening services among people living with HIV/AIDS Authors: Mingliang Jian, Dezhi Guo, Sisi Wang, Ti Liu, Haotian Qin, Xia Liu, Gen Su, Zhen Dai, Junguo Xin, Xiaohong Yang Published: 2026 ABSTRACT BackgroundThe high prevalence of HCV coinfection among people living with HIV/AIDS has become a serious public health issue. This study aimed to understand the prevalence of HCV coinfection and its associated factors among people living with HIV/AIDS who were under follow-up care, as well as to explore their preferences for HCV screening methods.MethodsThe study selected people living with HIV/AIDS who were receiving follow-up treatment in a district of Southwest China, up to September 30, 2025. Demographic information and details about the HIV infection route were collected from the HIV/AIDS follow-up management database. Blood samples were collected from these patients to test for anti-HCV and HCV core antigens. For those with positive HCV antibodies but negative core antigens, HCV RNA was quantitatively detected using high-precision methods. Multivariable logistic regression was used to analyze the factors influencing HCV coinfection among people living with HIV/AIDS. A discrete choice experiment was conducted to investigate the preferences of 219 people living with HIV/AIDS regarding four free HCV screening attributes: testing institutions, transportation subsidies, result collection time, and screening interval.ResultsA total of 1,014 people living with HIV/AIDS who were screened for anti-HCV and HCV core antigens were included in this study. Among them, 27 (2.66%) tested positive for HCV RNA or HCV core antigen. Multivariable logistic regression analysis revealed that the risk of HCV coinfection was 4.79 times higher in divorced or widowed individuals compared to married individuals with a spouse (95%CI: 1.76–13.01, P = 0.002). HIV/AIDS patients with a history of injecting drug use had a 41.70 times higher risk of HCV coinfection compared to those infected through heterosexual transmission (95%CI: 6.72–258.68, P < 0.001). The testing institution, transportation subsidies, and result collection time were key factors influencing participation in free HCV screening among people living with HIV/AIDS (all P < 0.05). Participants preferred HCV screening methods conducted at ART medication distribution sites (β = 1.685), with transportation subsidies of 50 yuan or less (β = 0.707), and same-day result collection (β = 0.269). The relative importance analysis of the attributes showed that the testing institution was the most important factor in choosing an HCV screening method (62.55%), followed by transportation subsidies (26.24%).ConclusionThe prevalence of HCV coinfection among people living with HIV/AIDS in a district of Southwest China is at a moderate to low level. Divorced or widowed individuals and those who inject drugs should be prioritized for HCV screening. Integrating HCV screening into ART medication dispensing sites, providing transportation subsidies, and improving the timeliness of result feedback may help increase the acceptance and accessibility of HCV screening among people living with HIV/AIDS.Clinical trial numberNot applicable.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12879-026-13727-3. Introduction Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) share similar transmission routes, including bloodborne transmission, sexual contact, and mother-to-child transmission, increasing the risk of HIV/HCV coinfection [1]. Globally, approximately 4 to 5 million HIV-infected or Acquired Immunodeficiency Syndrome (AIDS) patients are coinfected with HCV [2]. The prevalence of HCV coinfection varies among HIV/AIDS populations across different countries and regions in Asia. In Southeast Asia, a prospective cohort study conducted in Myanmar reported that approximately 6.5% of HIV/AIDS patients were coinfected with HCV [3]; in the HIV/AIDS population in Cambodia, the anti-HCV positive rate was about 6.8% [4]. In East Asian countries, the prevalence of HCV coinfection among HIV-infected individuals in South Korea was 5.2% [5]. in the general population in China, the anti-HCV positive rate is 0.60%, but the overall prevalence of HCV among HIV/AIDS patients is approximately 2.40% [6, 7], which is significantly higher than the general population’s HCV prevalence. The high prevalence of HCV coinfection among HIV/AIDS patients has become a serious public health issue. HIV and HCV coinfection interact to affect the natural history of the diseases, with coinfected individuals having a higher risk of all-cause and cause-specific mortality compared to those with a single infection [8, 9]. In the coinfected state, the immune function of the body remains impaired, leading to immune dysregulation, which accelerates the progression of HCV-related liver fibrosis and increases the risk of chronic hepatitis and liver cirrhosis decompensation [10]. Unlike HIV/AIDS, HCV is a chronic infectious disease that can be cured through treatment. Antiviral drugs (Direct-acting Antiviral Agents, DAA) can effectively improve the HCV cure rate in people coinfected with HIV/HCV. Evidence suggests that HCV-infected individuals who received 12 weeks of Sofosbuvir/Velpatasvir treatment achieved a cure rate of 95% [11]. In the United States, nearly 90% of chronic hepatitis C patients with liver complications experience delayed HCV diagnosis, and even during the period between 2015 and 2021 when DAA were introduced, about 75% of patients still had delayed diagnoses [12]. Most hepatitis C patients are not timely screened and diagnosed until they progress to hepatocellular carcinoma or decompensated liver disease, causing them to miss the early treatment window by the time of diagnosis [13]. In April 2016, the World Health Organization (WHO) proposed the goal of “eliminating the public health threat of viral hepatitis by 2030” at the 69th World Health Assembly. To continuously reduce the prevalence of HCV and ensure the health of the population, China developed the “Action Plan for Eliminating the Public Health Threat of Hepatitis C (2021–2030),” which includes strengthening HCV testing and early detection in key populations as a key measure [14]. People living with HIV are at high risk for HCV infection, but the distribution of their demographic and infection characteristics varies across different regions [15–17]. Hepatitis C is divided into acute and chronic phases based on the progression of the disease, with only 15% of acute HCV infections presenting with clinical symptoms [18]; About 70% of acute HCV patients fail to clear viremia within six months after infection and develop into chronic HCV infections [6]. Acute HCV infection is usually asymptomatic, and chronic HCV infection may also remain clinically silent for years before liver-related complications develop [19]. Opportunities for self-testing and seeking medical care are limited. Early screening for asymptomatic HCV infection relies largely on proactive offering by the healthcare system, and the way in which screening services are delivered is an important factor influencing screening uptake. Identifying high-risk population characteristics and scientifically planning the implementation of screening methods can help improve the efficiency of diagnosis and treatment, reducing the burden of adverse disease outcomes. The geographic distribution of the HIV epidemic in China is uneven, with a heavier disease burden in western China, including the southwest. A nationwide analysis in China showed that, compared with central China, western China had 3.56 times higher peak reporting rates, 4.74 times higher mortality, and 3.05 times higher prevalence of reported HIV/AIDS cases [20]. In addition, spatial epidemiological studies have shown that HIV/AIDS hotspots and high-clustering areas in China are mainly concentrated in the southwest, particularly in Yunnan, Guangxi, Sichuan, Guizhou, and Chongqing [21]. Recent national epidemic summaries in China have also indicated that the five provinces with the largest numbers of reported people living with HIV/AIDS are still predominantly located in the southwest [22]. A district in Southwest China is a key area for HIV/AIDS prevention and control. Previous studies have identified important correlates of HCV coinfection among people living with HIV/AIDS and have also examined service factors that may influence participation in HCV screening. However, these two issues have often been discussed separately. In practice, optimizing HCV screening services for people living with HIV/AIDS requires evidence not only on which subgroups are at higher risk of coinfection but also on which service features may improve the acceptability of screening. Therefore, this study aimed to estimate the prevalence of HCV coinfection among people living with HIV/AIDS in this region, examine its associated factors, and assess preferences for HCV screening service attributes using a discrete choice experiment (DCE). By integrating epidemiologic evidence with preference data within the same service context, this study seeks to provide practical evidence for optimizing HCV screening strategies in routine HIV/AIDS care. Methods Study design and population of HCV infection The study population for HCV infection identification comprised HIV/AIDS patients with an HIV diagnosis confirmed by immunoblotting at an AIDS confirmatory laboratory in a region of Southwest China by September 30, 2025, who had been enrolled in the HIV/AIDS follow-up database and were receiving follow-up care and treatment. We used a two-stage cluster sampling design. In the first stage, 17 HIV follow-up institutions were randomly selected from the list of HIV follow-up institutions in the district. In the second stage, participants who met the inclusion and exclusion criteria of this study were consecutively recruited within each selected institution until the target sample size was reached. The sample size was estimated using the following equation:\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:n={\left({z}_{\left(1-\alpha\:/2\right)}/\delta\:\right)}^{2}P\left(1-P\right)$$\end{document} The parameter n represents the required sample size for the study. Where P (prevalence of HIV/HCV coinfection) was taken as 2.4% which is based on a prior study conducted in China [7]. We took α as 0.05,\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\:{z}_{\left(1-\alpha\:/2\right)}$$\end{document} as 1.96, and 1% of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\delta\:$$\end{document} as an allowable error, the calculated sample size was 900. After adjustment for an anticipated nonresponse/invalid response rate of 10%, the minimum required sample size was approximately 1,000 participants [calculated as: minimum sample size = basic sample size ÷ (1 − expected nonresponse rate)].The inclusion criteria were: (1) People living with HIV/AIDS who were still under follow-up and receiving antiretroviral therapy (ART) in the district of Southwest China as of September 30, 2025; (2) People living with HIV/AIDS diagnosed at the age of 18 years or older. (3) Individuals who voluntarily consented to participate in this study and signed an informed consent form. The exclusion criteria were: (1) Patients with comorbid autoimmune hepatitis, malignant tumors, mental disorders, or other serious diseases; (2) Patients who were unable to participate in epidemiological investigations due to detention, compulsory drug rehabilitation, or other similar conditions. This research strictly adhered to the principles of the “WMA Declaration of Helsinki—Ethical Principles for Medical Research Involving Human Participants” and relevant Chinese laws and regulations. All participants provided voluntary informed consent after being fully informed of the research’s purpose and procedures. All personal information was anonymized throughout the research process. This research has been approved by the Medical Ethics Committee of the Chengdu Xindu District Disease Prevention and Control Center (Approval No. XDCDCIRB2025-005). Data collection for people living with HIV/AIDS and HCV infection testing Demographic and epidemiological data of people living with HIV/AIDS were collected from the HIV/AIDS follow-up management database in a district of Southwest China, which contains routinely updated and verified clinical records. This information included gender, age, marital status, education level, route of infection, and CD4+ T cell count, among others. The duration of ART was defined as the time interval from ART initiation to the time when the participant underwent HCV screening in this study, and the date of ART initiation was obtained from the HIV/AIDS follow-up management database. Venous blood samples (2.5 mL) were newly collected specifically for this study from eligible people living with HIV/AIDS during the study period; serum was then separated and stored at − 20 °C before laboratory testing. According to the “Laboratory Testing Technical Specifications for Hepatitis C Virus” (2023 revised version), the samples were tested for anti-HCV and HCV core antigens. Samples that were anti-HCV positive, but HCV core antigen negative were further tested for HCV RNA using high-precision quantitative methods. Coinfection with HCV was determined if any of the following conditions were met: (1) HCV core antigen positive; (2) Anti-HCV positive and HCV RNA high-precision quantitative detection positive. Participants of DCE The survey participants for the discrete choice experiment were consecutively recruited from HCV screening attendees at the 17 selected institutions who met the inclusion and exclusion criteria of this study until the target sample size was reached. The minimum sample size for the discrete choice experiment was calculated using the “thumb rule“ [23], with the formula: N ≥ 500c/(t×a), where 𝑐 is the maximum number of attribute levels, 𝑡 is the number of choice sets in each questionnaire, and 𝑎 is the number of options in each choice set. In this study, c was set to 2, a was 2, and t was 5. The calculation determined that the minimum sample size required for this study’s discrete choice experiment was 200 participants. The DCE of this study was implemented using an on-site, self-administered paper questionnaire. Before formal completion, trained interviewers explained the informed consent content and questionnaire instructions to participants face-to-face, including example choice questions, and confirmed that the participants understood how to complete the questionnaire. The participants then independently completed one of the two versions of the questionnaire. After completion, the interviewers checked the questionnaire for completeness and accuracy. Attribute and level setup of DCE The attributes and levels used in the DCE were determined through a combination of literature review, expert consultation, and local adaptation. Previous studies on preferences for HCV screening services and factors influencing HCV testing uptake among people living with HIV/AIDS were reviewed, and the identified factors were grouped accordingly. Four candidate attributes were identified: Testing location, Travel distance, Time to obtain test results, and Economic compensation [24–26]. Subsequently, two university-based epidemiology experts and two directors of relevant infectious disease control departments from centers for disease control and prevention were invited to discuss and screen the candidate attributes. The screening process was guided by the following principles: (a) relevance to the study objectives; (b) potential influence on respondents’ screening choices; (c) feasibility in real-world service settings; (d) conceptual independence between attributes; and (e) respondents’ cognitive burden. Finally, the wording of the attributes and the specification of their levels were further refined in light of the local HIV follow-up management process and the existing HCV screening practice in the study area. Four attributes were ultimately retained—Testing institution, Transportation subsidy, Result collection time, and Screening interval. Each attribute was specified at two levels. Table 1. Table 1Attributes and levels of the discrete choice experimentAttributeLevelDefinitionTesting institutionCenter for Disease Control and Prevention (CDC)The testing institution refers to the type of facility that provides anti-HCV, HCV core antigen, and high-precision quantitative HCV RNA testing services and issues test results.ART medication distribution siteTransportation subsidyNo subsidyTransportation subsidy refers to the cash compensation provided to individuals undergoing HCV screening/testing after each completed screening to offset round-trip transportation costs.≤ 50 yuanResult collection timeNot available on the same dayResult collection time refers to the period from completion of sample collection or testing to when the individual is able to obtain paper-based or electronic test results.Available on the same dayScreening intervalOnce every 6 monthsScreening interval refers to the time interval between two consecutive HCV screenings/tests.Once every year Table 1Attributes and levels of the discrete choice experimentAttributeLevelDefinitionTesting institutionCenter for Disease Control and Prevention (CDC)The testing institution refers to the type of facility that provides anti-HCV, HCV core antigen, and high-precision quantitative HCV RNA testing services and issues test results.ART medication distribution siteTransportation subsidyNo subsidyTransportation subsidy refers to the cash compensation provided to individuals undergoing HCV screening/testing after each completed screening to offset round-trip transportation costs.≤ 50 yuanResult collection timeNot available on the same dayResult collection time refers to the period from completion of sample collection or testing to when the individual is able to obtain paper-based or electronic test results.Available on the same dayScreening intervalOnce every 6 monthsScreening interval refers to the time interval between two consecutive HCV screenings/tests.Once every year Attributes and levels of the discrete choice experiment Choice set construction for the DCE Using SAS 9.4 software, an efficient orthogonal design was applied to attribute levels, generating 10 pairs of choice sets. The relative D-efficiency of the 10 choice-set pairs was 97.98%, indicating that the selected design had high efficiency for estimating the main effects. The maximum absolute correlation and mean absolute correlation were 0.030 and 0.012, respectively, indicating very low correlations among attributes and suggesting good near-orthogonality of the choice sets. In addition, both the maximum absolute deviation from 50% and the mean absolute deviation from 50% were 0, indicating that the design achieved perfect level balance. The orthogonal design matrix has been provided in the Supplementary Materials Supplementary Table 1. These 10 pairs were randomly assigned to two versions of the questionnaire using a random number method, with each version containing 5 choice sets. Respondents were randomly assigned to fill out one of the two versions. A sample of the choice sets is shown in Table 2. The complete DCE questionnaire used in this study is provided in the Supplementary Materials. Table 2Example of choice sets in the discrete choice experiment questionnaireAttributeOption 1Option 2Testing institutionCenter for Disease Control and Prevention (CDC)ART medication distribution siteTransportation subsidyNo subsidy≤ 50 yuanResult collection timeAvailable on the same dayNot available on the same dayScreening intervalOnce every 6 monthsOnce every yearWhich HCV screening method do you prefer?ŸŸ Table 2Example of choice sets in the discrete choice experiment questionnaireAttributeOption 1Option 2Testing institutionCenter for Disease Control and Prevention (CDC)ART medication distribution siteTransportation subsidyNo subsidy≤ 50 yuanResult collection timeAvailable on the same dayNot available on the same dayScreening intervalOnce every 6 monthsOnce every yearWhich HCV screening method do you prefer?ŸŸ Example of choice sets in the discrete choice experiment questionnaire Statistical methods Data management was performed using Microsoft Office Excel 2019, while data cleaning and statistical analysis were conducted using R Studio 4.5.1. The factors influencing HCV coinfection among people living with HIV/AIDS were analyzed. Qualitative data were described using frequency (percentage), and both univariate and multivariate analyses were performed using Logistic regression. For categorical variables with statistically significant differences in univariate analysis, multiple comparisons were conducted, and the Bonferroni method was used to adjust the significance level [27]. We performed diagnostic assessment of the fitted multivariable logistic regression model using the Hosmer–Lemeshow goodness-of-fit test and Cook’s distance diagnostics, and used Firth’s penalized likelihood logistic regression to examine the robustness of the original multivariable logistic regression results. The conditional logit model was used as the primary analytical model to assess the effects of attribute levels on choice preferences, whereas the panel mixed logit model was applied to account for within-respondent correlation arising from multiple choice tasks completed by the same individual and to further examine the robustness of the results after adjusting for demographic and epidemiological characteristics. Based on the regression coefficients from the panel mixed logit model, the relative importance scores of each attribute were further calculated. In the panel mixed logit model, all attributes were specified as random parameters with normal distributions. Correlation arising from repeated observations within the same respondent was addressed by setting panel = TRUE. The model was estimated by maximum simulated likelihood using 1,000 draws, with the default Halton sequence used for simulated integration. The significance level, α, was set to 0.05, unless otherwise specified. Results General demographic characteristics A total of 1,014 people living with HIV/AIDS were included in the study, of whom 760 (74.95%) were male. The majority (51.58%, 523/1014) were aged between 45 and 64 years. The predominant occupation was farming (38.66%, 392/1014). Among the participants, 52.66% (534/1014) were married with a spouse, and the educational level was primarily elementary school or below (36.00%, 365/1014) and middle school (37.48%, 380/1014). A total of 80.28% (814/1014) of participants were recorded in the HIV/AIDS follow-up management database as having acquired HIV through heterosexual transmission, while 12.62% (128/1014) had a baseline CD4 + T lymphocyte count of less than 200 cells/µl at the time of ART initiation. The median duration of ART was 3.21 years (IQR: 1.56–4.98 years). A total of 27 patients were coinfected with HCV, including 11 with positive HCV antigens and 16 with negative antigens but positive nucleic acid. The prevalence of HCV coinfection was 2.66%. Factors influencing HCV coinfection in people living with HIV/AIDS Gender, age, occupation, marital status, education level, route of infection, and CD4+ T lymphocyte count at ART enrollment were included in the univariate logistic regression model for HCV coinfection among people living with HIV/AIDS. The results showed statistically significant differences in HCV coinfection prevalence based on marital status and route of infection (P < 0.05), while there were no significant differences based on gender, age, or education level (P > 0.05).Multiple comparisons were performed for marital status and route of infection, with the corrected significance level α’ = 0.017. The results showed that the prevalence of HCV coinfection was significantly higher among divorced or widowed participants than among married participants with a spouse (5.37% [16/298] vs. 1.12% [6/534], P < 0.017). No significant differences were found between other marital status comparisons (P > 0.017). Additionally, the prevalence of HCV coinfection was significantly higher among participants who acquired HIV through injecting drug use than among those who acquired HIV through heterosexual transmission (57.14% [4/7] vs. 2.33% [19/814], P < 0.017). However, there were no significant differences in HCV coinfection prevalence between individuals infected through homosexual transmission and those infected through other routes. The HCV screening results for people living with HIV/AIDS were used as the dependent variable (coded as No = 0, Yes = 1), with gender, age, occupation, marital status, education level, route of infection, and CD4+ T lymphocyte count at ART enrollment as independent variables. A multivariable binary logistic regression analysis was performed using the enter method. The P-values of the Hosmer-Lemeshow tests were > 0.05, all Adjusted Generalized Variance Inflation Factor (GVIF) values were < 2.0, and the Cook’s distances for all observations were < 0.1, suggesting that the model showed acceptable fit, no substantial multicollinearity, and no influential observations Supplementary Table 2. The results showed that being divorced or widowed (OR = 4.79, 95%CI: 1.76–13.01, P = 0.002) and having HIV/AIDS transmitted through injection drug use (OR = 41.70, 95%CI: 6.72-258.68, P < 0.001) were significant risk factors for HCV coinfection. Table 3. Firth’s penalized likelihood logistic regression showed that being divorced or widowed (OR = 4.38, 95% CI: 1.75–12.21, P < 0.001) and acquiring HIV through injecting drug use (OR = 28.39, 95% CI: 5.56-164.19, P < 0.001) were significant risk factors for HCV coinfection, suggesting that the direction of the original regression results was relatively robust Supplementary Table 3. Table 3logistic regression analysis of factors associated with HCV coinfection among people living with HIV/AIDSCharacteristicsTotalHCV infection [n(%)]Univariate analysisMultivariate analysisYesNoOR (95%CI)P valueOR (95%CI)P value Gender Male76021 (2.76%)739 (97.24%)1.00(Ref.)1.00(Ref.)Female2546 (2.36%)248 (97.64%)0.85 (0.31–2.01)0.7310.60 (0.21–1.76)0.355 Age Group <45 years3579 (2.52%)348 (97.48%)1.00(Ref.)1.00(Ref.)45ཞ64 years52316 (3.06%)507 (96.94%)1.22 (0.54–2.91)0.6370.94 (0.30–2.90)0.910≥ 65 years1342 (1.49%)132 (98.51%)0.59 (0.09–2.31)0.4980.32 (0.05–1.99)0.221 Occupation Farmer39210 (2.55%)382 (97.45%)1.00(Ref.)1.00(Ref.)Worker721 (1.39%)71 (98.61%)0.54 (0.03–2.87)0.5570.29 (0.02–3.56)0.335Commercial services881 (1.14%)87 (98.86%)0.44 (0.02–2.34)0.4360.57 (0.07–4.90)0.609Domestic work, housekeeping, and unemployed2409 (3.75%)231 (96.25%)1.49 (0.58–3.75)0.3941.58 (0.58–4.29)0.367Other2226 (2.70%)216 (97.30%)1.06 (0.36–2.90)0.9100.73 (0.22–2.46)0.615 Marital status Married with a spouse①5346 (1.12%)528 (98.88%)1.00(Ref.)1.00(Ref.)Divorced or widowed②,a29816 (5.37%)282 (94.63%)4.99 (2.03–14.04)0.001*4.79 (1.76–13.01)0.002*Unmarried③1825 (2.75%)177 (97.25%)2.49 (0.71–8.35)0.1372.83 (0.64–12.54)0.170 Education level Primary school or below36512 (3.29%)353 (96.71%)1.00(Ref.)1.00(Ref.)Middle school38011 (2.89%)369 (97.11%)0.88 (0.38–2.03)0.7570.67 (0.25–1.77)0.415High school or secondary technical school1793 (1.68%)176 (98.32%)0.50 (0.11–1.60)0.2900.45 (0.10–2.03)0.297College degree or above901 (1.11%)89 (98.89%)0.33 (0.02–1.71)0.2910.34 (0.03–3.53)0.368 Route of infection Heterosexual transmission①81419 (2.33%)795 (97.67%)1.00(Ref.)1.00(Ref.)Homosexual transmission②1934 (2.07%)189 (97.93%)0.89 (0.25–2.39)0.8270.82 (0.23–2.88)0.752Injection drug use③,a74 (57.14%)3 (42.86%)55.79 (11.56-300.16)<0.001*41.70 (6.72–258.68)<0.001* CD4 + T lymphocyte count <200 cells/µl1283 (2.34%)125 (97.66%)1.00(Ref.)1.00(Ref.)200–350 cells/µl26310 (3.80%)253 (96.20%)1.65 (0.49–7.44)0.4551.78 (0.45–7.02)0.412351–499 cells/µl2806 (2.14%)274 (97.86%)0.91 (0.24–4.38)0.8980.90 (0.20–4.01)0.894≥ 500 cells/µl3438 (2.33%)335 (97.67%)0.99 (0.28–4.60)0.9940.98 (0.23–4.17)0.981Note: a: Compared with ①, P<0.017; *: P<0.05 Table 3logistic regression analysis of factors associated with HCV coinfection among people living with HIV/AIDSCharacteristicsTotalHCV infection [n(%)]Univariate analysisMultivariate analysisYesNoOR (95%CI)P valueOR (95%CI)P value Gender Male76021 (2.76%)739 (97.24%)1.00(Ref.)1.00(Ref.)Female2546 (2.36%)248 (97.64%)0.85 (0.31–2.01)0.7310.60 (0.21–1.76)0.355 Age Group <45 years3579 (2.52%)348 (97.48%)1.00(Ref.)1.00(Ref.)45ཞ64 years52316 (3.06%)507 (96.94%)1.22 (0.54–2.91)0.6370.94 (0.30–2.90)0.910≥ 65 years1342 (1.49%)132 (98.51%)0.59 (0.09–2.31)0.4980.32 (0.05–1.99)0.221 Occupation Farmer39210 (2.55%)382 (97.45%)1.00(Ref.)1.00(Ref.)Worker721 (1.39%)71 (98.61%)0.54 (0.03–2.87)0.5570.29 (0.02–3.56)0.335Commercial services881 (1.14%)87 (98.86%)0.44 (0.02–2.34)0.4360.57 (0.07–4.90)0.609Domestic work, housekeeping, and unemployed2409 (3.75%)231 (96.25%)1.49 (0.58–3.75)0.3941.58 (0.58–4.29)0.367Other2226 (2.70%)216 (97.30%)1.06 (0.36–2.90)0.9100.73 (0.22–2.46)0.615 Marital status Married with a spouse①5346 (1.12%)528 (98.88%)1.00(Ref.)1.00(Ref.)Divorced or widowed②,a29816 (5.37%)282 (94.63%)4.99 (2.03–14.04)0.001*4.79 (1.76–13.01)0.002*Unmarried③1825 (2.75%)177 (97.25%)2.49 (0.71–8.35)0.1372.83 (0.64–12.54)0.170 Education level Primary school or below36512 (3.29%)353 (96.71%)1.00(Ref.)1.00(Ref.)Middle school38011 (2.89%)369 (97.11%)0.88 (0.38–2.03)0.7570.67 (0.25–1.77)0.415High school or secondary technical school1793 (1.68%)176 (98.32%)0.50 (0.11–1.60)0.2900.45 (0.10–2.03)0.297College degree or above901 (1.11%)89 (98.89%)0.33 (0.02–1.71)0.2910.34 (0.03–3.53)0.368 Route of infection Heterosexual transmission①81419 (2.33%)795 (97.67%)1.00(Ref.)1.00(Ref.)Homosexual transmission②1934 (2.07%)189 (97.93%)0.89 (0.25–2.39)0.8270.82 (0.23–2.88)0.752Injection drug use③,a74 (57.14%)3 (42.86%)55.79 (11.56-300.16)<0.001*41.70 (6.72–258.68)<0.001* CD4 + T lymphocyte count <200 cells/µl1283 (2.34%)125 (97.66%)1.00(Ref.)1.00(Ref.)200–350 cells/µl26310 (3.80%)253 (96.20%)1.65 (0.49–7.44)0.4551.78 (0.45–7.02)0.412351–499 cells/µl2806 (2.14%)274 (97.86%)0.91 (0.24–4.38)0.8980.90 (0.20–4.01)0.894≥ 500 cells/µl3438 (2.33%)335 (97.67%)0.99 (0.28–4.60)0.9940.98 (0.23–4.17)0.981Note: a: Compared with ①, P<0.017; *: P<0.05 logistic regression analysis of factors associated with HCV coinfection among people living with HIV/AIDS Note: a: Compared with ①, P<0.017; *: P<0.05 Basic characteristics of participants in the discrete choice experiment A total of 219 HIV/AIDS patients completed the DCE questionnaire survey that passed quality control. The majority of participants were male (76.71%, 168/219). The age group of 45–64 years represented 47.49% (108/219) of the participants. Among the participants, 28.31% (62/219) were employed in domestic work, housekeeping, or were unemployed. A total of 43.84% (96/219) of participants were married with a spouse. The highest education level was predominantly middle school (37.44%, 82/219). The main route of HIV transmission was heterosexual contact (69.86%, 153/219), and 39.94% (87/219) of HIV/AIDS patients had a CD4+ T lymphocyte count between 200 and 350 cells/µl at ART enrollment. Table 4. Table 4Basic characteristics of participants in the discrete choice experiment (n = 219)FeatureNumber of cases (n)Proportion (%) Gender Male16876.71 Female5123.29 Age Group <45 years9844.75 45ཞ64 years10447.49 ≥ 65 years177.76 Occupation Farmer4520.55 Worker2712.33 Commercial services3114.16 Domestic work, housekeeping, and unemployed6228.31 Other5424.66 Marital status Married with a spouse9643.84 Divorced or widowed6730.59 Unmarried5625.57 Education level Primary school or below4520.55 Middle school8237.44 High school or secondary technical school5625.57 College degree or above3616.44 Route of infection Heterosexual transmission15369.86 Homosexual transmission6529.68 Injection drug use10.46CD4+ T lymphocyte count <200 cells/µl2310.30 200–350 cells/µl8739.94 351–499 cells/µl4721.55 ≥ 500 cells/µl6228.31 Table 4Basic characteristics of participants in the discrete choice experiment (n = 219)FeatureNumber of cases (n)Proportion (%) Gender Male16876.71 Female5123.29 Age Group <45 years9844.75 45ཞ64 years10447.49 ≥ 65 years177.76 Occupation Farmer4520.55 Worker2712.33 Commercial services3114.16 Domestic work, housekeeping, and unemployed6228.31 Other5424.66 Marital status Married with a spouse9643.84 Divorced or widowed6730.59 Unmarried5625.57 Education level Primary school or below4520.55 Middle school8237.44 High school or secondary technical school5625.57 College degree or above3616.44 Route of infection Heterosexual transmission15369.86 Homosexual transmission6529.68 Injection drug use10.46CD4+ T lymphocyte count <200 cells/µl2310.30 200–350 cells/µl8739.94 351–499 cells/µl4721.55 ≥ 500 cells/µl6228.31 Basic characteristics of participants in the discrete choice experiment (n = 219) Analysis of preferences for HCV screening methods among people living with HIV/AIDS In the conditional logit model, among the four attributes of HCV screening methods, the screening interval showed no statistical significance, while testing institution, transportation subsidies, and result collection time significantly influenced the choice of HCV screening method (P < 0.05). People living with HIV/AIDS preferred HCV screening methods where the testing institution was located at ART medication distribution sites (β = 0.767, P < 0.001), transportation subsidies of 50 yuan or less were provided (β = 0.348, P < 0.001), and the test results were available for collection on the same day (β = 0.132, P < 0.046). After controlling for individual characteristics and other factors, the results from the panel mixed logit model were consistent with those from the conditional logit model, with slightly higher regression coefficients. Table 5. Table 5Conditional logit and panel mixed logit regression analysis of the impact of HCV screening method attributes on screening preferencesAttribute and LevelConditional Logit ModelPanel Mixed Logit Model aβOR (95%CI)SEP valueβOR (95%CI)SEP valueTesting institution (reference: CDC) ART medication distribution site0.7672.15 (1.89, 2.46)0.068<0.001*1.6855.39 (3.48, 8.37)0.224<0.001*Transportation subsidy (reference: no subsidy) ≤ 50 yuan0.3481.42(1.24, 1.62)0.068<0.001*0.7072.03 (1.46, 2.82)0.169<0.001*Result collection time (reference: not available on the same day) Available on the same day0.1321.14 (1.02, 1.30)0.0670.046*0.2691.31(1.02, 1.68)0.1270.034*Screening interval (reference: once every 6 months) Once every year-0.0350.97 (0.84, 1.11)0.0690.611-0.0330.97 (0.72, 1.30)0.1500.828 Log likelihood -662.428-564.222 AIC 1332.8551164.444 BIC 1352.8491254.417Note: a: Adjusted for gender, age group, occupation, marital status, education level, route of infection, and CD4+ T lymphocyte count; *:P<0.05 Table 5Conditional logit and panel mixed logit regression analysis of the impact of HCV screening method attributes on screening preferencesAttribute and LevelConditional Logit ModelPanel Mixed Logit Model aβOR (95%CI)SEP valueβOR (95%CI)SEP valueTesting institution (reference: CDC) ART medication distribution site0.7672.15 (1.89, 2.46)0.068<0.001*1.6855.39 (3.48, 8.37)0.224<0.001*Transportation subsidy (reference: no subsidy) ≤ 50 yuan0.3481.42(1.24, 1.62)0.068<0.001*0.7072.03 (1.46, 2.82)0.169<0.001*Result collection time (reference: not available on the same day) Available on the same day0.1321.14 (1.02, 1.30)0.0670.046*0.2691.31(1.02, 1.68)0.1270.034*Screening interval (reference: once every 6 months) Once every year-0.0350.97 (0.84, 1.11)0.0690.611-0.0330.97 (0.72, 1.30)0.1500.828 Log likelihood -662.428-564.222 AIC 1332.8551164.444 BIC 1352.8491254.417Note: a: Adjusted for gender, age group, occupation, marital status, education level, route of infection, and CD4+ T lymphocyte count; *:P<0.05 Conditional logit and panel mixed logit regression analysis of the impact of HCV screening method attributes on screening preferences Note: a: Adjusted for gender, age group, occupation, marital status, education level, route of infection, and CD4+ T lymphocyte count; *:P<0.05 Relative importance of attributes Based on the results of the panel mixed logit model, the relative importance of each attribute was calculated. The findings showed that the most important attribute for people living with HIV/AIDS in choosing an HCV screening method was the testing institution (62.55%), followed by transportation subsidies (26.24%). The importance of result collection time (9.99%) was ranked higher than that of the screening interval (1.22%) Fig. 1. Fig. 1Relative importance proportions of HCV screening method attributes among people living with HIV/AIDS. Note: A: Testing institution; B: Transportation subsidy; C: Result collection time; D: Screening interval Relative importance proportions of HCV screening method attributes among people living with HIV/AIDS. Note: A: Testing institution; B: Transportation subsidy; C: Result collection time; D: Screening interval Discussion Epidemiological characteristics and influencing factors of HCV coinfection among people living with HIV/AIDS This study analyzed the epidemiological characteristics and related factors of HCV coinfection among people living with HIV/AIDS in a district of Southwest China. The results indicated that the prevalence of HCV coinfection among HIV/AIDS patients in this area was 2.66%. A higher prevalence was observed among divorced or widowed individuals and those infected through injection drug use compared with married individuals with a spouse. The multivariable regression results showed that, compared to married individuals with a spouse and those infected through heterosexual transmission, divorce or widowhood and injection drug use were risk factors for HCV coinfection in people living with HIV/AIDS. The prevalence of HCV coinfection among people living with HIV/AIDS in this district was similar to the national prevalence of HIV/HCV coinfection among people living with HIV/AIDS in China [7]. However, it was slightly lower than the prevalence reported in other studies from Southwest China, such as Yunnan Province [28] (5.48%), Guizhou Province [29] (6.55%) and Guangxi Zhuang Autonomous Region [30] (5.41%). The prevalence observed in this district was higher than that reported in Renshou County, Sichuan Province [31] (1.4%). HIV and HCV share similar transmission routes. Epidemiological studies indicate that the risk of HCV infection among people living with HIV is approximately six times higher than in HIV-negative individuals [32]. In cases of percutaneous blood exposure, the risk of HCV infection is about 10 times higher than that of HIV [33]. In recent years, over 97% of new HIV infections in China have occurred through sexual transmission, which increases the risk of HCV infection in HIV/AIDS patients [34]. Additionally, HIV infection can increase the risk of vertical transmission of HCV from mother to child [35]. In this study, 80.28% of people living with HIV/AIDS acquired HIV through heterosexual transmission, which is consistent with previous studies and suggests that sexual transmission may represent an important epidemiological context for HCV coinfection among people living with HIV/AIDS in this area. Compared to married individuals, people living with HIV/AIDS who are divorced or widowed have a higher risk of HCV coinfection. This finding is consistent with the results of a study by Wan et al. (2022) [36] conducted in the Pudong New District of Shanghai. It suggests that a disrupted marital status may be a risk factor for HCV coinfection in people living with HIV/AIDS. Marital status is an important socio-structural factor that may influence the risk of disease infection by altering an individual’s behavior patterns, health awareness, and social support systems. The changes in partner structure due to divorce or widowhood may influence sexual behavior patterns. A sexual behavior survey among adults in the United States found that widowed, divorced, and separated individuals had a higher proportion of new sexual partners in the past year compared to married or cohabiting individuals [37]. Additionally, compared with those living with a spouse or having a steady sexual partner, individuals without a regular partner were more likely to engage in commercial heterosexual sex and were less likely to use condoms [38, 39], which may be associated with an increased risk of sexually transmitted infections. Prior studies have indicated that major marital disruptions such as divorce or widowhood are positively associated with psychological stress symptoms, including depression, anxiety, and stress [40, 41]. These negative psychological states can, to some extent, affect an individual’s ability to process health information, their sensitivity to health risks, and their adoption of protective behaviors [42]. As suggested by previous studies, the psychosocial stress arising after divorce or widowhood may affect health-related behaviors and healthcare utilization among people living with HIV/AIDS. Social support is one of the most important psychosocial predictors of physical health [43]. Married individuals generally have higher levels of social support compared to unmarried, divorced, or widowed individuals [44, 45]. Patients with higher levels of family economic and emotional support are at lower risk for negative health outcomes [46]. Divorced or widowed people living with HIV/AIDS may receive less emotional support, financial security, and caregiving from their families, increasing their exposure to environments where they may be at higher risk of HCV infection. This contributes to their elevated risk of HCV coinfection. The research findings of Pan et al. (2023) [47], Wang et al. (2023) [48], and Xie et al. (2019) [49] all indicate that people living with HIV/AIDS who are infected through intravenous drug use have a higher risk of HCV coinfection compared to those infected through heterosexual or homosexual sexual contact, which is consistent with the results of this study. In recent years, the ongoing HIV prevention and health education measures targeting drug users in Southwest China have shown positive effects; however, there is a noticeable increase in the use of new types of drugs [50]. Compared to traditional drugs, new drugs have more complex mechanisms of action, primarily involving receptor-mediated and non-receptor-mediated cellular regulation, accompanied by interactions among various neurotransmitter systems. The receptors activated by these drugs and the neurotransmitter systems exhibit widespread overlap [51], which can produce stronger hallucinatory effects, impair mood control and cognitive function, and potentially make users more prone to engaging in high-risk sexual behaviors such as sexual promiscuity, anal sex, and unprotected intercourse [52], increasing the risk of disease transmission. In cases of percutaneous blood exposure, the infectivity of HCV is approximately 10 times higher than that of HIV, and HCV can survive in syringes for up to several weeks [53]. Intravenous drug use involves multiple high-risk behaviors, including the sharing or reuse of needles or syringes and injection accessories such as filters and spoons used for dissolving drugs, creating a frequent environment for viral percutaneous blood exposure [54]. HIV infection impairs the body’s specific immune response to HCV, and among HIV/HCV coinfected individuals, the likelihood of HCV recurrence after initial viral control is higher [55]. For individuals infected with HIV through injection drug use, unsafe injection practices leading to bloodborne exposure combined with impaired immune function may increase the risk of HIV/HCV coinfection. Preferences for HCV screening methods among people living with HIV/AIDS In studies related to disease screening preferences, demographic factors may have a certain impact on the choice of screening methods. For example, in colorectal cancer screening in the United States, the screening utilization rate was lower among individuals aged 45–49 compared to those aged 50–75 [56]. At the county level research, education level was positively correlated with participation in mammography screening [57]. Regarding gender, studies show that both men and women believe cancer screening is effective, but men are less likely to participate in cancer and skin cancer screenings compared to women [58]. Therefore, when analyzing the impact of HCV screening method attributes on preferences, it is necessary to control for individual characteristics. After controlling for demographic and epidemiological factors, the results indicated that the testing institution, transportation subsidies, and result collection time significantly influenced HCV screening preferences. People living with HIV/AIDS preferred HCV screening methods where the testing institution was located at ART medication distribution sites, with transportation subsidies of 50 yuan or less, and the ability to collect results on the same day. Among these factors, the testing institution and transportation subsidies had relatively higher importance. The results of this study are similar to those of Radley et al. [26], who examined the preferences for hepatitis C testing service attributes among individuals receiving opioid substitution therapy. Studies conducted in Taiwan [59], Australia [60], and the United States [61] also show that the choice of screening institution, economic compensation, and the timeliness of test results are associated with individuals’ willingness to participate in HCV screening. The relative importance of the testing institution was much higher than that of other attributes, with people living with HIV/AIDS showing a clear preference for HCV testing at ART medication distribution sites. This pattern of results suggests that participants placed greater value on the accessibility and convenience of screening services than on the screening frequency itself. The strong preference for screening at ART medication dispensing sites may indicate that participants were more inclined to receive integrated services within existing and familiar care settings, as this could reduce additional travel, coordination, and time costs. In this study, the participants in the discrete choice experiment were mainly engaged in domestic work, housekeeping, or were unemployed, indicating relatively low economic income. Previous studies have shown that transportation costs and accessibility are significant barriers to healthcare utilization for low-income populations, and economic support such as transportation subsidies can improve access to healthcare and reduce the immediate barriers to participation in screening [62, 63]. Receiving HCV test results on the same day may reduce uncertainty and psychological burden during the waiting period and may help improve completion of the screening process [64, 65]. These findings suggest that in efforts to increase HCV screening coverage among people living with HIV/AIDS, priority should be given to optimizing the service delivery structure and reducing additional healthcare burdens, rather than solely relying on economic incentives or adjusting screening frequency. Conclusion The prevalence of HCV coinfection among people living with HIV/AIDS in this district is at a moderate to low level compared to the southwest region of China, with notable differences across populations based on marital status and infection routes. Divorced or widowed individuals, as well as those infected through injection drug use, exhibit a higher risk of HCV coinfection. People living with HIV/AIDS show a preference for HCV screening methods conducted at ART medication distribution sites, with transportation subsidies provided and the ability to collect test results on the same day. Disease prevention and control programs should prioritize HCV screening for people living with HIV/AIDS who are divorced or widowed and for those who acquired HIV through injecting drug use. At the same time, HCV screening strategies should not stop at risk stratification. Health services should integrate HCV screening into existing ART service settings and reduce the additional burden of seeking care, thereby increasing screening uptake among people living with HIV/AIDS. These findings may provide practical evidence for optimizing HCV screening services for people living with HIV/AIDS in similar settings. Limitations and perspectives This study has several limitations. Some potentially eligible participants were not included in the final analysis because they were unable or unwilling to complete the study procedures, resulting in missing study-specific HCV test results or other key data required for analysis. These exclusions may introduce selection bias into the results. To reduce the burden on participants, economic cost-related information was not collected in the discrete choice experiment, and as a result, patients’ willingness to pay for HCV screening was not analyzed in this experiment. Because the number of HCV coinfection events was limited and some categorical subgroups were small, conventional multivariable logistic regression may have yielded unstable estimates. Although the sensitivity analysis using Firth’s penalized likelihood logistic regression showed broadly consistent results, the effect sizes should be interpreted with caution. Although a two-level design helps improve questionnaire feasibility and completion, it may limit the ability to detect more nuanced differences in preferences. Information on HCV status at HIV diagnosis or ART initiation was unavailable; therefore, previously existing HCV infection could not be distinguished from infection identified during the current study period. Future studies could, on the basis of a larger sample, incorporate additional attribute levels or more diverse service scenarios. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2